Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Intercept Pharmaceuticals (NASDAQ:ICPT), a clinical-stage developer of therapies focused on chronic liver diseases, fell as much as $136, or 31%, after reporting additional data from its pivotal Flint trial on obeticholic acid (OCA) as a treatment for nonalcoholic steathohepatitis (NASH) on Sunday.
So what: Intercept's press release, which mainly touched on the subject of why the study was stopped early due to statistically significant efficacy, also noted that "lipid abnormalities involving increased total cholesterol and LDL and decreased HDL were seen in OCA-treated patients compared to placebo." As a reminder, HDL cholesterol is considered the bad type of cholesterol physicians and researchers are always trying to lower while raising HDL, the good kind of cholesterol. Intercept notes in its press release that lipid abnormalities are common in NASH patients and it will review its data to determine whether or not these lipids return to pre-treatment levels.
Now what: I said on Friday following Intercept's 545% run higher that the clinical data had better be perfect from here on out or the share price could get clobbered – and today we're seeing what happens with potentially not-so-perfect data. Ultimately, these lipid abnormalities may indeed just be a cause-and-effect of NASH. Then again, the chance that OCA is causing these abnormalities is more than enough reason for speculators to at least consider taking some money off the table after what's truly been a historic two-day run. Personally, I get seasick just looking at the weekly chart on Intercept and would suggest sticking to the sidelines until we have a better idea of why the OCA-treated population saw their bad cholesterol levels rise relative to the control arm.
Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.